• HOME
  • INVESTMENTS
    • Equities >
      • Australia All Cap
      • Australia Small Cap Income
      • Global Mobility
      • Global High Conviction
    • Property >
      • Listed Property
      • TAMIM Property
    • Income >
      • Credit
  • INSIGHTS
    • Insights
    • Weekly Reading Lists
  • ABOUT
  • CONTACT
Tamim Asset Management
  • HOME
  • INVESTMENTS
    • Equities >
      • Australia All Cap
      • Australia Small Cap Income
      • Global Mobility
      • Global High Conviction
    • Property >
      • Listed Property
      • TAMIM Property
    • Income >
      • Credit
  • INSIGHTS
    • Insights
    • Weekly Reading Lists
  • ABOUT
  • CONTACT

Stock Insights

Stock Review: Sugi Holdings Co.

22/1/2020

0 Comments

 
Kevin Smith, of Delft Partners and portfolio manager of the TAMIM Asia Small Companies Fund, highlights one of the stocks in the Asia Small Companies portfolio. 
SUGI HOLDINGS CO. LTD. (Sugi) is a Japan-based holding company mainly engaged in the management of retail pharmacy stores.  Sugi is engaged in the sale of medicines, health foods, cosmetics, daily necessities and prescription preparations.  Sugi also operates visiting nursing stations that closely cooperate with regional medical institutions and social welfare operators, through the provision of visiting nursing services and in-home nursing care support services.  In November 2019 Sugi operated a total of 1,271 stores (including nursing stations) and employed 6,237 full-time in addition to 10,456 part-time staff.
​​Accounting, Strategy and Governance Comments

Accounting
​
  1. Full compliance Japanese GAAP accounting standards which are largely equivalent to IFRS.  The accounts are overseen by three outside auditors in accord with standard practice in Japan.
  2. Sugi pays a full corporate tax rate in excess of 30%.
  3. Sugi publishes earnings on a quarterly basis, updating full year earnings per share and dividend per share forecasts with each set of results.  Sugi also publishes monthly sales figures, therefore providing better transparency than is typical in Japan.
Strategy
​

  1. Sugi has an excellent history of growth and has sensible plans going forward that doesn't rely on increased prescription values.  The average prescription value for Sugi peaked at ¥ 11,270 in 2016 and had fallen to ¥ 10,660 in the quarterly reporting for Q3 2019.  
  2. Sugi has a strategy directed to growing the number of stores, the Q3 accounts indicated a total of 1,271 stores which is expected to rise to 1,290 by March 2020 an 8.4% increase from the March 2019 total of 1,190.  Growth rates of new stores varies by region with the more mature regions of Chubu and Kansai growing at a 5% rate while the Kanto and Hokuriku regions are growing at a double digit pace.  Growth is directed towards the Sugi branded stores, the company had an earlier alliance (2005) and then merger (2013) with Japan Co. Ltd which brought in stores branded “Japan”. The “Japan” brand looks likely to be phased out over time.  Sugi has a target for 110 new stores in 2020 and 120 new stores in 2021.  In addition to building new stores Sugi is increasing the number of stores providing their “home care” visiting service which has a positive impact on revenue per client.
  3. Sugi is gradually increasing the sales area of their stores, in 2014 the average sales area was 578 m2  which is expected to achieve an average of 603 m2  by the end of 2020.  Sugi has a total of 16,693 full and part-time employees with 62.6% employed on a part-time basis.  The ratio of part-time employees has increased from 57.7% in 2014, which gives Sugi more flexibility in the management of the business.  Sugi’s annual investment in new stores amounts to ¥14,500 million and the spend on existing stores is ¥3,000 million which combines for a total equivalent to USD 160 million.  Sugi’s investment rate is running at twice the rate of depreciation and is funded from internal resources.
  4. Sugi has achieved very good diversification of sales with prescriptions accounting for 21.7% of the total, there is a good spread across other categories including healthcare products (20%), health foods (19%) and beauty products (21%).  The gross profit margin for prescriptions exceeds all other categories at 38.5% versus the overall average of 31.2%.  Sugi has managed to improve the overall gross margin from 29.8% in the past year.
Picture
Picture
Picture
Source: Sugi Holdings Full Year Results 2019
Governance
​
  1. Sugi has three independent directors on the Board comprising seven directors.  The Sugiura family control 32.5% of the share capital and they have three family members sitting on the Board.  Continuing involvement of the Sugiura family is a positive for the business.
  2. In June 2019 the Board announced a possible business integration with Cocokara Fine Co. Ltd.  In August 2019 the discussions were terminated without an agreement being reached.  The Board took the view that prospects for their business were better without the prospect of an eventual merger of a business that is 50% the size of Sugi.  We prefer Sugi looking to grow their business in the existing manner without taking on a relatively large and complex merger.
  3. Sugi is fully compliant with the governance regulations in Japan.  
  4. The dividend payout ratio has increased during the past decade, hitting a low point of 9.8% in 2010 to the current level of 27%.  There is scope for further increases in the dividend payout ratio.
Picture
Source: Sugi Holdings Full Year Results 2019
Value, Momentum and Quality Comments

  1. Sugi  has a long history of delivering revenue and profits growth by expanding the number of stores.  The company has developed from filling 500,000 prescriptions per annum in 2003 to 8.7 million by 2019.  Sugi operates in a sector that attracts high valuations, the forward P/E of 18.3x is reasonable versus the sector average in excess of 20x. 
  2. Return on capital employed in excess of 11% helps to underpin strength in the score for quality.  The company has a strong balance sheet with no debt and generates positive free cash flow each year.   The company can comfortably fund the new stores expansion programme from operating income.
  3. There are just six analysts covering the stock and they have upgraded their 2021 earnings forecasts by 9% in the past year.  The company has delivered positive earnings surprise in each of the past three years, in 2019 the actual earnings exceeded expectations by 9.8%.
Picture
Picture
Source: Market Screener
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Stock Commentary

    At TAMIM we are committed to educating investors on how best to manage their retirement futures.

    Sign up to receive our weekly newsletter:

    * indicates required

    TAMIM Asset Management provides general information to help you understand our investment approach. Any financial information we provide is not advice, has not considered your personal circumstances and may not be suitable for you.

    Archives

    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    December 2015

    Categories

    All
    2016 Presidential Election
    5G
    AGM Season
    Apple (AAPL.NASDAQ)
    Asia Small Companies
    ASX
    ATL.AX
    Aus Equity All Cap Portfolio
    Aus Equity All Cap Value Portfolio
    Aus Equity Growth Portfolio
    Aus Equity Income Portfolio
    Aus Equity Small Cap Portfolio
    Australian Stocks
    Autonomous Vehicles
    Big Four Banks
    Brexit
    Electric Vehicles
    Emerging Markets
    Energy
    ENN.AX
    FAANG
    Financials
    Fintech
    Global Equity High Conviction Portfolio
    Global Mobility
    Gmg.ax
    Gold
    Growth Stocks
    Guy Carson
    Healthcare
    Income Investing
    Infrastructure
    International Stocks
    Investment Thematics
    IT Services
    Mergers & Acquisitions
    Mobility
    Pharma
    Property
    Rare Earths
    REITs
    Reporting Season
    Retail
    Robert Swift
    Ron Shamgar
    SLK.AX
    Small Cap Income Portfolio
    Small Caps
    Stock Report
    Takeovers
    Technology
    Telco Stocks
    Telstra (TLS.ASX)
    Tourism
    TPG
    Utilities
    Value Investing
    Video
    Wesfarmers (WES.ASX)

    RSS Feed

TAMIM | Equities | Property | Credit
​

TAMIM Fund
Australia All Cap
Australia Small Cap Income
Global Mobility
Global High Conviction
Credit

Listed Property
TAMIM Property
Company
About
Contact
Insights
Invest Online
Login
Other
Privacy Policy
Terms & 
Conditions
​Disclaimer
Contact
Level 4, 55 Grafton Street
Bondi Junction, Sydney NSW, 2022

1300 750 007

ima@tamim.com.au

DISCLAIMER

​The information provided on this website should not be considered financial or investment advice and is general information intended only for wholesale clients ( as defined in the Corporations Act). If you are not a wholesale client, you should exit the website. The content has been prepared without taking into account your personal objectives, financial situations or needs. You should seek personal financial advice before making any financial or investment decisions. Where the website refers to a particular financial product, you should obtain a copy of the relevant product services guide or offer document for wholesale investors before making any decision in relation to the product. Investment returns are not guaranteed as all investments carry some risk. The value of an investment may rise or fall with the changes in the market. Past performance is no guarantee of future performance. This statement relates to any claims made regarding past performance of any Tamim (or associated companies) products. Tamim does not guarantee the accuracy of any information in this website, including information provided by third parties. Information can change without notice and Tamim will endeavour to update this website as soon as practicable after changes. Tamim Funds Management Pty Limited and CTSP Funds Management Pty Ltd trading as Tamim Asset Management and its related entities do not accept responsibility for any inaccuracy or any actions taken in reliance upon this advice. All information provided on this website is correct at the time of writing and is subject to change due to changes in legislation. Please contact Tamim if you wish to confirm the currency of any information on the website.  

magellen, kosec, clime, wilson, wam, montgomery, platinum, commsec, caledonia, pengana, tamim

  • HOME
  • INVESTMENTS
    • Equities >
      • Australia All Cap
      • Australia Small Cap Income
      • Global Mobility
      • Global High Conviction
    • Property >
      • Listed Property
      • TAMIM Property
    • Income >
      • Credit
  • INSIGHTS
    • Insights
    • Weekly Reading Lists
  • ABOUT
  • CONTACT